HPC
RLAY icon

HM Payson & Co’s Relay Therapeutics RLAY Stock Holding History

HM Payson & Co’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-979
Closed -$34K – 1152
2021
Q1 		$34K Hold
979
– – ﹤0.01% 678
2020
Q4 		$41K Sell
979
-250
-20% -$11.3K ﹤0.01% 636
2020
Q3 		$52K Buy
+1,229
New +$46.9K ﹤0.01% 558

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HM Payson & Co's RLAY Position: Q2 2021 in Review

HM Payson & Co sold out of Relay Therapeutics (RLAY) in Q2 2021, closing a stake of 979 shares — an estimated $34K sold.

HM Payson & Co first reported a position in RLAY in Q3 2020 and held it in 3 quarters. The position peaked at $52K in Q3 2020. 125 funds tracked by Wall St. Rank hold RLAY as of Q2 2021.

  • HM Payson & Co reported no remaining Relay Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HM Payson & Co sold 979 Relay Therapeutics shares in Q2 2021, an estimated $34K.
  • HM Payson & Co first reported a position in Relay Therapeutics in Q3 2020 and held it in 3 quarters.
  • HM Payson & Co's Relay Therapeutics position peaked at $52K in Q3 2020.
  • 125 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.